STOCK TITAN

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host its Annual General Meeting (AGM) on May 20, 2022, at 10:30 a.m. CEST in Marseille, France. The AGM will be broadcasted live, and only registered shareholders can participate. Shareholders must register their shares at least two business days before the AGM. The Notice of Meeting published on April 8, 2022, includes the agenda and proposed resolutions. Documentation for the AGM is available on the Company’s website.

Positive
  • AGM allows shareholders to participate and vote, promoting transparency.
  • The presence of major alliances with leading biopharmaceutical companies enhances trust and potential for growth.
Negative
  • Limited participation due to the requirement of share registration two days prior to the AGM.

The Annual General Meeting will be broadcasted live by the Company

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 20, 2022 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Annual General Meeting will be broadcasted live.

The Notice of Meeting of this AGM was published on April 8, 2022 in the French legal bulletin. It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.

All documentation regarding this AGM will be published on the Company’s website along with the dial-in details for the live broadcast.

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by zero hour Paris time, will be able to participate.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the voting or proxy form.

Written questions from shareholders must be received the second business days prior to the AGM at the latest (by e-mail to investors@innate-pharma.fr).

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to investors@innate-pharma.fr.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code
Ticker code
LEI

 

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors and Media



Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr



ATCG Press

Marie Puvieux (France)

Tel.: +33 981 87 46 72

innate-pharma@atcg-partners.com

Source: Innate Pharma SA

FAQ

What date is Innate Pharma's Annual General Meeting (AGM)?

Innate Pharma's AGM is on May 20, 2022.

What time will the AGM of Innate Pharma start?

The AGM will start at 10:30 a.m. CEST.

Where will Innate Pharma's AGM be held?

The AGM will be held at 117 avenue de Luminy, Marseille, France.

How can I participate in the AGM of Innate Pharma?

Shareholders must register their shares at least two business days prior to the AGM.

What is required for shareholders holding bearer shares to participate in the AGM?

They need to obtain a certificate of shareholding from their brokers.

Innate Pharma S.A. ADS

NASDAQ:IPHA

IPHA Rankings

IPHA Latest News

IPHA Stock Data

170.53M
80.95M
0.5%
0.08%
Biotechnology
Healthcare
Link
United States of America
Marseille